MedTrace Logo

A Noninvasive Test for Fetal RHD Genotype

NCT00871195 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 520

Last updated 2012-05-10

No results posted yet for this study

Summary

The objective of this study is to evaluate the performance of Sequenom's noninvasive test for fetal RHD genotype. The test uses MALDI-TOF mass spectrometry to detect DNA. The study is specifically designed to determine whether RHD typing using free fetal DNA in maternal circulation can accurately predict the neonatal RhD phenotype at birth.

Conditions

  • Rhesus D Genotype

Sponsors & Collaborators

  • NAFTNet

    collaborator OTHER

  • Sequenom, Inc.

    lead INDUSTRY

Principal Investigators

  • Kenneth Moise, MD · Baylor College of Medicine

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2011-11-30
Completion
2012-04-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871195 on ClinicalTrials.gov